DNTH (Dianthus Therapeutics) Defensive Interval Ratio


DNTH Dianthus Therapeutics Inc DNTH
22 GF Score
Price $94.34
GF Value $2.91
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Dianthus Therapeutics Defensive Interval Ratio?

DNTH
22GF Score
Dianthus Therapeutics Inc DNTH
Defensive Interval Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Dianthus Therapeutics (DNTH) Overvalued in 2026?

Based on GuruFocus' analysis, Dianthus Therapeutics stock appears to be overvalued. The current stock price of $94.34 is trading 3141.9% above its estimated GF Value™ of $2.91. GuruFocus considers Dianthus Therapeutics to be Significantly Overvalued.

Key valuation signals for DNTH:

  • Defensive Interval Ratio:
  • GF Value™: $2.91 vs. price of $94.34 (3141.9% above fair value)
  • GF Score™: 22/100 with 7 warning signs

No single metric tells the full story. See the DNTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Dianthus Therapeutics Business Description

Other Exchanges 87E:Germany
Address 7 Times Square, 43rd Floor, New York, NY, USA, 10036
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
22GF Score

Get the complete analysis for DNTH

Defensive Interval Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$94.34
Price
$2.91
GF Value